Marked response to imatinib mesylate in metastatic acral lentiginous melanoma on the thumb
Marked response to imatinib mesylate in metastatic acral lentiginous melanoma on the thumb
复制标题
甲磺酸伊马替尼对拇指转移性肢端雀斑样黑色素瘤有显着疗效
DOI：
10.1111/j.1365-2230.2010.03885.x
复制
发表时间：
2011
影响因子：
4.1
通讯作者：
Shimada S
中科院分区：
文献类型：
--
作者：
Yamaguchi M;Harada K;Ando N;Kawamura T;Shibagaki N;Shimada S
我们报告一例黑色素瘤，有一个显着的反应与甲磺酸伊马替尼（IM）治疗。患者是一名61岁男性，拇指上有一个红色小结节，甲盖破坏。在组织学检查中，该病变被诊断为黑色素瘤，计算机断层扫描显示左腋窝淋巴结肿胀和双肺野结节。尽管患者接受了干扰素-β的瘤内注射和达卡巴嗪的全身给药，但原发性和转移性病灶的大小均增加。免疫化学检测到aKIT突变，经DNA测序分析证实，患者接受IM治疗。在开始IM方案的2周内，甲板上结节的大小显著减小，腋窝淋巴结肿胀和肺结节形成消退。该病例表明IM可能是KIT突变阳性黑色素瘤的一种有希望的治疗选择。
We report a case of melanoma that had a marked response to treatment with imatinib mesylate (IM). The patient was a 61‐year‐old man who presented with a small red nodule on the thumb and destruction of the nail plate. On histological examination, this lesion was diagnosed as a melanoma, and computed tomography revealed lymph‐node swelling in the left axilla and nodules in both lung fields. Although the patient received intratumoral injections of interferon‐β and systemic administration of dacarbazine, both primary and metastatic lesions increased in size. Immunochemistry detected aKITmutation, which was confirmed by DNA sequencing analysis, and patient was given IM. Within 2 weeks of starting the IM regimen, the size of the nodule on the nail plate markedly decreased, and the axillary lymph‐node swelling and lung‐nodule formation regressed. This case suggests that IM may be a promising treatment option forKITmutation‐positive melanoma.